Signal transducer and activator of transcription proteins in leukemias

Blood

Volumn 101, Issue 8, 2003, Pages 2940-2954

  Benekli, Mustafa ^a   Baer, Maria R ^a   Baumann, Heinz ^a   Wetzler, Meir ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; STAT PROTEIN; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DNA BINDING PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; ISOPROTEIN; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, MOUSE; JANUS KINASE 2; MILK PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE; STAT5 PROTEIN; STAT6 PROTEIN; STAT6 PROTEIN, HUMAN; STAT6 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN; TUMOR PROTEIN;

CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHROMOSOMAL LOCALIZATION; CYTOPLASM; HEMATOPOIESIS; HUMAN; KNOCKOUT MOUSE; LEUKEMIA; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; ANIMAL; BONE MARROW CELL; CHEMISTRY; CLASSIFICATION; CYTOLOGY; DRUG ANTAGONISM; DRUG DESIGN; FORECASTING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; NEOPLASM; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; DRUG DESIGN; FORECASTING; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; JANUS KINASE 2; LEUKEMIA; MICE; MICE, KNOCKOUT; MILK PROTEINS; MYELOID CELLS; NEOPLASM PROTEINS; NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROTEIN ISOFORMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS;

EID: 0038820386     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1204     Document Type: Review

References (257)

1. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995;64:621-651.
2. Ihle JN. STATs: signal transducers and activators of transcription. Cell. 1996;84:331-334.
3. Darnell JE Jr. STATs and gene regulation. Science. 1997;277:1630-1635.
4. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000;37:1-11.
5. Takeda K, Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 2000;11:199-207.
6. Williams JG. STAT signaling in cell proliferation and in development. Curr Opin Genet Dev. 2000;10:503-507.
7. Bromberg JF. Activation of STAT proteins and growth control. Bioessays. 2001;23:161-169.
8. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell. 1995;80:213-223.
9. Wells JA, de Vos AM. Hematopoietic receptor complexes. Annu Rev Biochem. 1996;65:609-634.
10. Shuai K, Stark GR, Kerr IM, Darnell JE Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science. 1993;261:1744-1746.
11. Sadowski HB, Shuai K, Darnell JE Jr, Gilman MZ. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science. 1993;261:1739-1744.
12. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415-1421.
13. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996;84:443-450.
14. Meraz MA, White JW, Sheehan KJF, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996;84:431-442.
15. Levy DE. Physiological significance of STAT proteins: investigations through gene disruption in vivo. Cell Mol Life Sci. 1999;55:1559-1567.
16. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse STAT3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A. 1997;94:3801-3804.
17. Duncan SA, Zhong Z, Wen Z, Darnell JE. STAT signaling is active during early mammalian development. Dev Dyn. 1997;208:190-198.
18. Takeda K, Kaisho T, Yoshida N, et al. STAT3 activation is responsible for IL-6 dependent T-cell proliferation through preventing apoptosis: generation and characterization of T-cell specific STAT3-deficient mice. J Immunol. 1998;161:4652-4660.
19. Akaishi H, Takeda K, Kaisho T, et al. Defective IL-2-mediated IL-2 receptor α chain expression in STAT3-deficient T lymphocytes. Int Immunol. 1998;10:1747-1751.
20. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of STAT3 in macrophages and neutrophils. Immunity. 1999;10:39-49.
21. Sano S, Itami S, Takeda K, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 1999;18:4657-4668.
22. Chapman RS, Lourenco PC, Tonner E, et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev. 1999;13:2604-2616.
23. Kaplan MH, Sun Y-L, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in STAT4-deficient mice. Nature. 1996;382:174-177.
24. Thierfelder WE, van Deursen JM, Yamamoto K, et al. Requirement of STAT4 in interleukin-12 mediated immune responses of natural killer and T cells. Nature. 1996;382:171-174.
25. Liu X, Robinson GW, Wagner K, et al. STAT5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997;11:179-186.
26. Udy GB, Towers RP, Snell RG, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A. 1997;94:7239-7244.
27. Feldman GM, Rosenthal LA, Liu X, et al. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood. 1997;90:1768-1776.
28. Nakajima H, Liu XW, Wynshaw-Boris A, et al. An indirect effect of STAT5a in IL-2 induced proliferation: a critical role for STAT5a in IL-2-mediated IL-2 receptor α chain induction. Immunity. 1997;7:691-701.
29. Imada K, Bloom ET, Nakajima H, et al. STAT5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med. 1998;188:2067-2074.
30. Teglund S, McKay C, Schuetz E, et al. STAT5a and STAT5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93:841-850.
31. Socolovsky M, Fallon AE, Wang S, et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999;98:181-191.
32. Moriggl R, Topham DJ, Teglund S, et al. STAT5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999;10:249-259.
33. Takeda K, Kamanaka M, Tanaka T, et al. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol. 1996;157:3220-3222.
34. Takeda K, Tanaka T, Shi W, et al. Essential role of STAT6 in IL-4 signaling. Nature. 1996;380:627-630.
35. Shimoda K, van Deursen J, Sangster MY, et al. Lack of IL-4 induced Th2 response and IgE class switching in mice with disrupted STAT6 gene. Nature. 1996;380:630-633.
36. Kaplan MH, Schindler U, Smiley ST, Gruspy MJ. STAT6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity. 1996;4:313-319.
37. Copeland NG, Gilbert DJ, Schindler C, et al. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics. 1995;29:225-228.
38. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell. 1998;93:827-839.
39. Becker S, Bernd G, Muller CW. Three-dimensional structure of the Stat3 beta homodimer bound to DNA. Nature. 1998;394:145-151.
40. Vinkemeier U, Cohen SL, Moarefi I, et al. DNA binding of in vitro activated STAT1a, STATb and truncated STAT1: interaction between NH-2 terminal domains stabilizes binding of two dimers to tandem NA sites. EMBO J. 1996;15:5616-5626.
41. Xu X, Sun YL, Hoey T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino terminal domain. Science. 1996;273:794-797.
42. Horvath CM, Wen Z, Darnell JE. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 1995;9:984-994.
43. Schindler U, Wu P, Rothe M, Brasseur M, McKnight SL. Components of a STAT recognition code: evidence for two layers of molecular selectivity. Immunity. 1995;2:689-697.
44. Horvath CM, Darnell JE. The state of STATs: recent developments in the study of signal transduction to the nucleus. Curr Opin Cell Biol. 1997;9:233-239.
45. Shuai K, Horvath CM, Huang LHT, Qureshi SA, Cowburn D, Darnell JE Jr. Interferon activation of the transcription factor STAT91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell. 1994;76:821-828.
46. Haan S, Hemmann U, Hassiepen U, et al. Characterization and binding specificity of the monomeric STAT3-SH2 domain. J Biol Chem. 1999;274:1342-1348.
47. Heim MH, Kerr IM, Stark GR, Darnell JE Jr. STAT SH2 groups contribute to specific interferon signaling by the Jak-STAT pathway. Science. 1995;267:1347-1349.
48. Shuai K, Ziemiecki A, Wilks AF, et al. Polypeptide signaling to the nucleus through tyrosine phosphorylation of JAK and STAT proteins. Nature. 1993;366:580-583.
49. Gupta S, Yan H, Wong LH, Ralph S, Krolewski J, Schindler C. The SH2 domain of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN alpha signals. EMBO J. 1996;15:1075-1084.
50. Leonard WJ, O'Shea JJ. JAKS and STATS: biological implications. Annu Rev Immunol. 1998;16:293-322.
51. Moriggl R, Berchtold S, Friedrich K, et al. Comparison of the transactivation domains of STAT5 and STAT6 in lymphoid cells and mammary epithelial cells. Mol Cell Biol. 1997;17:3663-3678.
52. Hoey T, Schindler U. STAT structure and function in signalling. Curr Opin Genet Dev. 1998;8:582-587.
53. Kim H, Baumann H. The carboxyl-terminal region of STAT3 controls gene induction by the mouse haptoglobin promoter. J Biol Chem. 1997;272:14571-14579.
54. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene. 2000;19:2628-2637.
55. Decker T, Kovarik P. Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. Cell Mol Life Sci. 1999;55:1535-1546.
56. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 1995;267:1990-1994.
57. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82:241-250.
58. Turkson J, Bowman T, Adnane J, et al. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol. 1999;19:7519-7528.
59. Bromberg JF, Horvath CM, Besser D, et al. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol. 1998;18:2553-2558.
60. Caldenhoven E, van Dijk TB, Solari R, et al. STAT3b, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem. 1996;271:13221-13227.
61. Chakraborty A, White SM, Schafer TS, et al. Granulocyte colony-stimulating factor activation of STAT3 alpha and STAT3 beta in immature normal and leukemic human myeloid cells. Blood. 1996;88:2442-2449.
62. Schaefer TS, Sanders LK, Nathans D. Cooperative transcriptional activity of jun Stat3b, a short form of Stat3. Proc Natl Acad Sci U S A. 1995;92:9097-9101.
63. Schaefer TS, Sanders LK, Park OK, Nathans D. Functional differences between Stat3α and Stat3β. Mol Cell Biol. 1997;17:5307-5316.
64. Wang D, Stravopodis D, Teglund S, Kitazawa J, Ihle JN. Naturally occurring dominant negative variants of Stat5. Mol Cell Biol. 1996;16:6141-6148.
65. Moriggl R, Gouilleux-Gruart V, Jahne R, et al. Deletion of the carboxyl-terminal transactivation domain of MGF-STAT5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol. 1996;16:5691-5698.
66. Mui AL, Wakao H, Kinoshita T, et al. Suppression of interleukin-3-induced gene expression by a c-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J. 1996;15:2425-2433.
67. Azam M, Erdjument-Bromage H, Kreider BL, et al. Interleukin-3 signals through multiple isoforms of Stat5. EMBO J. 1995;14:1402-1411.
68. Hevehan DL, Miller WM, Papoutsakis ET. Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood. 2002;99:1627-1637.
69. Azam M, Lee C, Strehlow I, Schindler C. Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity. 1997;6:691-701.
70. Meyer J, Jucker M, Otertag W, Stocking C. Carboxyl-truncated STAT5 beta is generated by nucleus-associated serine protease in early hematopoietic progenitors. Blood. 1998;91:1901-1908.
71. Lee C, Piazza F, Brutsaert S, et al. Characterization of the Stat5 protease. J Biol Chem. 1999;274:26767-26775.
72. Xia Z, Salzler RR, Kunz DP, et al. A novel serine-dependent proteolytic activity is responsible for truncated signal transducer and activator of transcription proteins in acute myeloid leukemia blasts. Cancer Res. 2001;61:1747-1753.
73. Xia Z, Baer MR, Block AW, et al. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res. 1998;58:3173-3180.
74. Akira S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells. 1999;17:138-146.
75. Akira S. Role of STAT3 defined by tissue-specific gene targeting. Oncogene. 2000;19:2607-2611.
76. Levy DE, Gilliland DG. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene. 2000;19:2505-2510.
77. Smithgall TE, Briggs SD, Schreiner S, et al. Control of myeloid differentiation and survival by STATs. Oncogene. 2000;19:2612-2618.
78. Coffer PJ, Koenderman L, de Groot RP. The role of STATs in myeloid differentiation and leukemia. Oncogene. 2000;19:2511-2522.
79. Shimozaki K, Nakajima K, Hirano T, Nagata S. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J Biol Chem. 1997;272:25184-25189.
80. Minami M, Inoue M, Wei S, et al. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A. 1996;93:3963-3966.
81. Nakajima K, Yamanaka Y, Nakae K, et al. A central role for STAT3 in IL-6 induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996;15:3651-3658.
82. Tomida M, Heike T, Yokota T, et al. Cytoplasmic domains of the leukemia inhibitory factor receptor required for STAT3 activation, differentiation, and growth arrest of myeloid leukemic cells. Blood. 1999;93:1934-1941.
83. Nemetz C, Hocke GM. Transcription factor STAT5 is an early marker of differentiation of murine embryonic stem cells. Differentiation. 1998;62:213-220.
84. Niwa H, Burdon T, Chambers I, Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998;12:2048-2060.
85. Ernst M, Novak U, Nicholson SE, et al. The carboxyl-terminal domains of gp130-related cytokine receptors are necessary for suppressing embryonic stem cell differentiation. Involvement of STAT3. J Biol Chem. 1999;274:9729-9737.
86. Ward AC, Smith L, de Koning JP, et al. Multiple signals mediate proliferation, differentiation, and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells. J Biol Chem. 1999;274:14956-14962.
87. Chakraborty A, Tweardy DJ. Stat3 and G-CSF-induced myeloid differentiation. Leuk Lymphoma. 1998;30:433-442.
88. de Koning JP, Soede-Bobok AA, Ward AC, et al. STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene. 2000;19:3290-3298.
89. Chakraborty A, Dyer KF, Cascio M, et al. Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood. 1999;93:15-24.
90. Nicholson SE, Starr R, Novak U, et al. Tyrosine residues in the granulocyte colony-stimulating factor (G-CSF) receptor mediate G-CSF-induced differentiation of murine myeloid leukemic (M1) cells. J Biol Chem. 1996;271:26947-26953.
91. Nosaka T, Kawashima T, Misawa K, et al. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 1999;18:4754-4765.
92. Ilaria RL Jr, Hawley RG, Van Etten RA. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood. 1999;93:4154-4166.
93. Kieslinger M, Woldman I, Moriggl R, et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 2000;14:232-244.
94. Ripperger JA, Fritz S, Richter K, Hocke GM, Lottspeich F, Fey GH. Transcription factors STAT3 and STAT5b are present in rat liver nuclei late in an acute phase response and bind interleukin-6 response elements. J Biol Chem. 1995;270:29998-30006.
95. Lokuta MA, McDowell MA, Paulnock DM. Identification of an additional isoform of STAT5 expressed in immature macrophages. J Immunol. 1998;161:1594-1597.
96. Piazza F, Valens J, Lagasse E, Schindler C. Myeloid differentiation of FdCP1 cells is dependent on Stat5 processing. Blood. 2000;96:1358-1365.
97. Caldenhoven E, van Dijk TB, Tijmensen A, et al. Differential activation of functionally distinct STAT5 proteins by IL-5 and GM-CSF during eosinophil and neutrophil differentiation from human CD34+ hematopoietic stem cells. Stem Cells. 1998;16:397-403.
98. Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci. 1998;5:79-85.
99. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474-2488.
100. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a STAT3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269:81-83.
101. Cao X, Tay A, Guy GR, Tan YH. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol. 1996;16:1595-1603.
102. Turkson J, Bowman T, Garcia R, et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998;18:2545-2552.
103. Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001;20:2499-2513.
104. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115.
105. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Curr Opin Oncol. 1999;11:490-496.
106. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol. 1999;29:3945-3950.
107. Puthier D, Thabard W, Rapp M, et al. Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 antiapoptotic molecule. Br J Haematol. 2001;112:358-363.
108. Grandis JR, Zeng Q, Drenning SD. Epidermal growth factor receptor-mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope. 2000;110(5 Pt 1):868-874.
109. Grandis JR, Drenning SD, Zeng Q, Watkins SC. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A. 2000;97:4227-4232.
110. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene. 2000;19:2489-2495.
111. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999;98:295-303.
112. De Vos J, Jourdan M, Tarte K, et al. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol. 2000;109:823-828.
113. Hayakawa F, Towatari M, Iida H, et al. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br J Haematol. 1998;101:521-528.
114. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997;278:1803-1805.
115. Goh KC, Haque SJ, Williams BR. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 1999;18:5601-5608.
116. Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res. 2000;2:86-90.
117. Reddy MVR, Chaturvedi P, Reddy EP. Src kinase mediated activation of STAT3 plays an essential role in the proliferation and oncogenicity of human breast, prostate and ovarian carcinomas [abstract]. Proc Am Assoc Cancer Res. 1999;40:376.
118. Garcia R, Yu CL, Hudnall A, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997;8:1267-1276.
119. Sartor CI, Dziubinski ML, Yu CL, et al. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res. 1997;57:978-987.
120. Watson CJ, Miller WR. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer. 1995;71:840-844.
121. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest. 1998;102:1385-1392.
122. Zhou MY, Zeng Q, Drenning SD, Grandis R. Differential activation of STAT5 isoforms and growth control in head and neck cancer [abstract]. Proc Am Assoc Cancer Res. 1999;40:335.
123. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer. 1999;83:564-570.
124. Gao B, Shen X, Kunos G, et al. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett. 2001;488:179-184.
125. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of STAT3 signaling pathway. Prostate. 2000;42:239-242.
126. Frank DA, Mahajan S, Yuan H. The chemoprotectant butyrate downregulates IL-6 induced signaling events in colorectal carcinoma cells [abstract]. Proc Am Assoc Cancer Res. 1999;40:318.
127. Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999;59:5059-5063.
128. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000;19:2548-2556.
129. Rawat R, Rainey GJ, Thompson CD, et al. Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas. Blood. 2000;96:3514-3521.
130. Yu CL, Jove R, Burakoff SJ. Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J Immunol. 1997;159:5206-5210.
131. Weber-Nordt RM, Egen C, Wehinger J, et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood. 1996;88:809-816.
132. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137-5144.
133. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107:351-362.
134. Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci U S A. 1997;94:13897-13902.
135. Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 1995;269:79-81.
136. Kirken RA, Erwin RA, Wang L, Wang Y, Rui H, Farrar WL. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells. J Immunol. 2000;165:5097-5104.
137. Karras JG, McKay RA, Lu T, et al. STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression. Cell Immunol. 2000;202:124-135.
138. Zhang Q, Nowak I, Vonderheid EC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci U S A. 1996;93:9148-9153.
139. Eriksen KW, Kaltoft K, Mikkelsen G, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001;15:787-793.
140. Nielsen M, Kaltoft K, Nordahl M, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A. 1997;94:6764-6769.
141. Nielsen M, Kaestel CG, Eriksen KW, et al. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 1999;13:735-738.
142. Kube D, Holtick U, Vockerodt M, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood. 2001;98:762-770.
143. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618-626.
144. Dearoff CR. JAKs and STATs in invertebrate model organisms. Cell Mol Life Sci. 1999;55:1578-1584.
145. Hou XS, Perrimon N. The JAK-STAT pathway in Drosophila. Trends Genet. 1997;13:105-110.
146. Luo H, Dearolf CR. The JAK/STAT pathway and Drosophila development. Bioessays. 2001;23:1138-1147.
147. Binari R, Perrimon N. Stripe-specific regulation of pair-rule genes by hopscotch, a putative Jak family tyrosine kinase in Drosophila. Genes Dev. 1994;8:300-312.
148. Yan R, Small S, Desplan C, Dearolf CR, Darnell JE Jr. Identification of a Stat gene that functions in Drosophila development. Cell. 1996;84:421-430.
149. Hou XS, Melnick MB, Perrimon N. Marella acts downstream of the Drosophila HOP/JAK kinase and encodes a protein similar to the mammalian STATs. Cell. 1996;84:411-419.
150. Yan R, Luo H, Darnell JE Jr, Dearolf CR. A JAK-STAT pathway regulates wing vein formation in Drosophila. Proc Natl Acad Sci U S A. 1996;93:5842-5847.
151. Hanratty WP, Ryerse JS. A genetic melanotic neoplasm of Drosphila melanogester. Dev Biol. 1981;83:238-249.
152. Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N. Activation of a Drosophila Janus Kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J. 1995;14:2857-2865.
153. Luo H, Hanratty WP, Dearolf CR. An amino acid substitution in the Drosophila hop Tum-1 Jak kinase causes leukemia-like hematopoietic defects. EMBO J. 1995;14:1412-1420.
154. Luo H, Rose P, Barber D, et al. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak/Stat pathways. Mol Cell Biol. 1997;17:1562-1571.
155. Dexter TM, Lajtha LG. Proliferation of hematopoietic stem cells in vitro. Br J Haematol. 1974;28:525-530.
156. Sensebe L, Deschaseaux M, Li J, Herve P, Charbord P. The broad spectrum of cytokine gene expression by myeloid cells from the human marrow microenvironment. Stem Cells. 1997;15:133-143.
157. Wetzler M, Kurzrock R, Estrov Z, Estey E, Talpaz M. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leuk Res. 1995;19:23-34.
158. Lowenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood. 1993;81:281-292.
159. Kirito K, Nagashima T, Ozawa K, Komatsu N. Constitutive activation of Stat1 and Stat3 in primary erythroleukemia cells. Int J Hematol. 2002;75:51-54.
160. L gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. J Biol Chem. 2002;277:8329-8337.
161. Kirito K, Uchida M, Yamada M, Miura Y, Komatsu N. A distinct function of STAT proteins in erythropoietin signal transduction. J Biol Chem. 1997;272:16507-16513.
162. Spiekermann K, Biethahn S, Wilde S, Hiddemann W, Alves F. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol. 2001;67:63-71.
163. Biethahn S, Alves F, Wilde S, et al. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol. 1999;27:885-894.
164. Gouileux-Gruart V, Gouileux F, Desaint C, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 1996;87:1692-1697.
165. Aronica MG, Brizzi MF, Dentelli P, Rosso A, Yarden Y, Pegoraro L. p91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells. Oncogene. 1996;13:1017-1026.
166. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia. 2001;15:1923-1931.
167. Benekli M, Xia Z, Donohue KA, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002;99:252-257.
168. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 2000;95:3765-3770.
169. Koistinen P, Saily M, Poromaa N, Savolainen ER. Complex effects of interleukin 6 on clonogenic blast cell growth in acute myeloblastic leukemia. Acta Haematol. 1997;98:14-21.
170. Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol. 2002;30:262-271.
171. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr-Abl. J Exp Med. 1996;183:811-820.
172. Ilaria RL Jr, Van Etten RA. P210 and P190(Bcr-Abl) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31704-31710.
173. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
174. Lacronique V, Boureux A, Monni R, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood. 2000;95:2076-2083.
175. Karakas T, Maurer U, Weidmann E, et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9:159-165.
176. Andreeff M, Jiang S, Zhang X, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881-1892.
177. Xia Z, Sait SN, Baer MR, et al. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res. 2001;25:473-482.
178. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631.
179. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96:3907-3914.
180. Niu G, Wright KL, Huang M, et al. Constitutive STAT3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000-2008.
181. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309-313.
182. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637-2644.
183. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
184. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717-3721.
185. Verstovsek S, Kantarjian H, Manshouri T, et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002;99:2265-2267.
186. Arnould C, Philippe C, Bourdon V, Grgoire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet. 1999;8:1741-1749.
187. Maurer AB, Wichmann C, Gross A, et al. The Stat5-RARa fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood. 2002;99:2647-2652.
188. Dong S, Tweardy DJ. Interactions of STAT5b-RARa, a novel acute
189. Bennett J, Catovsky D, Daniel M, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med. 1985;103:626-629.
190. Slack JL. Biology and treatment of acute progranulocytic leukemia. Curr Opin Hematol. 1999;6:236-240.
191. Matikainen S, Ronni T, Hurme M, Pine R, Julkunen I. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood. 1996;88:114-123.
192. Matikainen S, Ronni T, Lehtonen A, et al. Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Differ. 1997;8:687-698.
193. Matikainen S, Lehtonen A, Sareneva T, Julkunen I. Regulation of IRF and STAT gene expression by retinoic acid. Leuk Lymphoma. 1998;30:63-71.
194. Pelicano L, Li F, Schindler C, Chelbi-Alix MK. Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action. Oncogene. 1997;15:2349-2359.
195. Gianni M, Terao M, Fortino I, et al. Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood. 1997;89:1001-1012.
196. Garattini E, Mologni L, Ponzanelli I, Terao M. Cross-talk between retinoic acid and interferons: molecular mechanisms of interaction in acute promyelocytic leukemia cells. Leuk Lymphoma. 1998;30:467-475.
197. Dimberg A, Nilsson K, Oberg F. Phosphorylation-deficient Stat1 inhibits retinoic acid-induced differentiation and cell cycle arrest in U-937 monoblasts. Blood. 2000;96:2870-2878.
198. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9; 12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535-2540.
199. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL-JAK2 fusion genes. EMBO J. 1998;17:5321-5333.
200. Ho JM, Beattie BK, Squire JA, et al. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood. 1999;93:4354-4364.
201. Carron C, Cormier F, Janin A, et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood. 2000;95:3891-3899.
202. Schwaller J, Parganas E, Wang D, et al. STAT5 is essential for the myelo- and lymphoproliferative disease induced by TEL-JAK2. Mol Cell. 2000;6:693-704.
203. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cell through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol. 2001;21:3547-3557.
204. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
205. Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by the v-abl oncogene. Science. 1995;269:1875-1877.
206. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene. 2000;19:2523-2531.
207. Frank DA, Varticovski L. BCR-abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia. 1996;10:1724-1730.
208. Shuai K, Halpern J, ten Hoeve J, et al. Constitutive activation of STAT5 by the Bcr-Abl oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247-254.
209. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in Bcr-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159:4720-4728.
210. Sillaber C, Gesbert F, Frank DA, et al. STAT5 activation contributes to growth and viability in Bcr-Abl-transformed cells. Blood. 2000;95:2118-2125.
211. de Groot RP, Raaijmakers JA, Lammers JW, et al. STAT5 activation by Bcr-Abl contributes to transformation of K562 leukemia cells. Blood. 1999;94:1108-1112.
212. Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by Bcr-Abl is dependent on intact Src homology (SH)3 and SH2 domains of Bcr-Abl and is required for leukemogenesis. J Exp Med. 1999;189:1229-1242.
213. Nieborowska-Skorska M, Slupianek A, Skorski T. Progressive changes in the leukemogenic signaling in Bcr-Abl-transformed cells. Oncogene. 2000;19:4117-4124.
214. Gesbert F, Griffin JD. Bcr-Abl activates transcription of the Bcl-x gene through STAT5. Blood. 2000;96:2269-2276.
215. L expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun. 2000;3:299-305.
216. L. J Exp Med. 2000;191:977-984.
217. Donato NJ, Wu JY, Zhang L, et al. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in Bcr-Abl (+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after Bcr-Abl inhibition. Blood. 2001;97:2846-2853.
218. Sexl V, Piekorz R, Moriggl R, et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of Stat5. Blood. 2000;96:2277-2283.
219. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
220. Palmer AM, Mahajan S, Frank D, Gilliland DG, Carroll M. The TEL-PDGFβR transforming protein activates STAT1 [abstract]. Blood. 1997;90:178a.
221. Sternberg DW, Tomasson M, Carroll M, et al. The TEL-PDGFR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood. 2001;98:3390-3397.
222. Keating MJ. Chronic lymphocytic leukemia. Semin Oncol. 1999;26(5 Suppl 14):107-114.
223. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997;100:3140-3148.
224. Frank DA. STAT signaling in the pathogenesis and treatment of cancer. Mol Med. 1999;5:432-456.
225. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000;19:2496-2504.
226. Seidel HM, Lamb P, Rosen J. Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene. 2000;19:2645-2656.
227. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000;19:6613-6626.
228. Demartis A, Bernassola F, Savino R, Melino G, Ciliberto G. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res. 1996;56:4213-4218.
229. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991;78:1198-1204.
230. Meydan N, Grunberger T, Harjit D, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379:645-648.
231. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
232. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 2001;19:378-387.
233. Alexander WS, Starr R, Fenner JE, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 1999;98:597-608.
234. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921-924.
235. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997;387:924-929.
236. Liu B, Liao J, Rao X, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA. 1998;95:10626-10631.
237. Ram PA, Waxman DJ. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem. 1999;274:35553-35561.
238. Kamura T, Sato S, Haque D, et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 1998;12:3872-3881.
239. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene. 2000;19:2638-2644.
240. Collum RG, Brutsaert S, Lee G, Schindler C. A Stat3-interacting protein (StlP1) regulates cytokine signal transduction. Proc Natl Acad Sci U S A. 2000;97:10120-10125.
241. Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem. 1997;272:17694-17702.
242. You M, Yu DH, Feng GS. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol. 1999;19:2416-2424.
243. Woetmann A, Nielsen M, Christensen ST, et al. Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci U S A. 1999;96:10620-10625.
244. Yu CL, Jin YJ, Burakoff SJ. Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation. J Biol Chem. 2000;275:599-604.
245. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276:45443-45455.
246. Marra F, Choudhury GG, Abboud HE. Interferon-gamma-mediated activation of STAT1alpha regulates growth factor-induced mitogenesis. J Clin Invest. 1996;98:1218-1230.
247. Mann MJ, Dzau VJ. Therapeutic implications of transcription factor decoy oligonucleotides. J Clin Invest. 2000;106:1071-1075.
248. Boccaccio C, Ando M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998;391:285-288.
249. Huang JS, Guh JY, Hung WC, et al. Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. Biochem J. 1999;342(pt 1):231-238.
250. Wang LH, Yang XY, Kirken RA, Resau JH, Farrar WL. Targeted disruption of STAT6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven T(H)2 cell response. Blood. 2000;95:1249-1257.
251. Morris EC, Carrell RW, Coughlin PB. Intracellular serpins in haemopoietic and peripheral blood cells. Br J Haematol. 2001;115:758-766.
252. Kirkwood JM, Farkas DL, Chakraborty A, et al. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med. 1999;5:11-20.
253. Sun WH, Pabon C, Alsayed Y, et al. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood. 1998;91:570-576.
254. Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3 gamma. J Biol Chem. 1997;272:28779-28885.
255. Chelbi-Alix MK, Pelicano L. Retinoic acid and interferon signaling cross-talk in normal and RA-resistant APL cells. Leukemia. 1999;13:1167-1174.
256. Kolla V, Lindner DJ, Xiao W, Borden EC, Kalvakolanu DV. Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem. 1996;271:10508-10514.
257. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999;5:444-447.